This page shows the SEC filing summaries for Biofrontera Inc..
Biofrontera Inc.
CIK: 1858685 · 3 filings tracked
Filing History
1
10-K
Annual Report
March 19, 2026
- Sales grew 12% to $28.5 million in 2025, showing Ameluz® is gaining market share.
- Completed enrollment for a Phase 3 trial for Ameluz® in basal cell carcinoma, with top results expected in late 2026, signaling potential market expansion.
- Dermatologist prescriptions for Ameluz® increased by 15% in 2025, indicating growing doctor trust and adoption.
2
8-K
Material Event
March 19, 2026
- Biofrontera Inc. reported record sales of $10.3 million for Q4 2025, a significant increase from $7.6 million last year.
- The company achieved a profit of $5.6 million in Q4 2025, a major turnaround from a $5.0 million loss in Q4 2024.
- Biofrontera Inc. gained full ownership of key U.S. products (Ameluz® and RhodoLED®) and reduced costs through a new earnout structure (12%-15% vs. 25%-35%).
3
8-K
Material Event
January 7, 2026
- Biofrontera Inc. received a Nasdaq warning notice for failing to maintain a minimum stock price of $1.00.
- The company's stock traded below $1.00 for 34 consecutive business days, triggering the non-compliance notice.
- Failure to regain compliance within 180 days could lead to delisting from Nasdaq, impacting stock liquidity and the company's ability to raise capital.
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.